Literature DB >> 8152352

Isoniazid prophylaxis: the importance of individual values.

J G Dolan1, D R Bordley.   

Abstract

To provide insight into the decision whether to use isoniazid prophylaxis in uncomplicated cases of positive tuberculin tests, the authors conducted a multicriteria decision analysis using the analytic hierarchy process. If reducing the chance of developing active tuberculosis is considered at least slightly more important than avoiding isoniazid-related side effects, isoniazid prophylaxis is the better strategy for all patients. If avoiding isoniazid-related side effects is considered at least slightly more important, no prophylaxis is the better strategy for all patients. If these two considerations are judged equally important, the better strategy depends on patient age, the anticipated effectiveness of isoniazid prophylaxis, and whether or not the patient is a recent tuberculin convertor. The tradeoff between avoiding active tuberculosis and avoiding isoniazid-related side effects is the most important factor in the decision regarding the proper management of patients with positive tuberculin tests. These results emphasize the importance of taking an individualized approach to the management of these patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8152352     DOI: 10.1177/0272989X9401400101

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  10 in total

1.  Public involvement in health care priority setting: an overview of methods for eliciting values.

Authors:  Penelope M. Mullen
Journal:  Health Expect       Date:  1999-12       Impact factor: 3.377

Review 2.  Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature.

Authors:  Kevin Marsh; Tereza Lanitis; David Neasham; Panagiotis Orfanos; Jaime Caro
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

3.  The use of multiattribute decision models in evaluating triptan treatment options in migraine.

Authors:  M D Ferrari; P J Goadsby; R B Lipton; D W Dodick; F M Cutrer; D McCrory; P Williams
Journal:  J Neurol       Date:  2005-03-11       Impact factor: 4.849

Review 4.  Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.

Authors:  David W Dodick; Richard B Lipton; Michel D Ferrari; Peter J Goadsby; Douglas McCrory; F Michael Cutrer; Paul Williams
Journal:  Curr Pain Headache Rep       Date:  2004-12

5.  Patient priorities in colorectal cancer screening decisions.

Authors:  James G Dolan
Journal:  Health Expect       Date:  2005-12       Impact factor: 3.377

6.  Agreement of decision analyses and subsequent clinical studies in infectious diseases.

Authors:  Joshua N Bress; Todd Hulgan; Jennifer A Lyon; Cecilia P Johnston; Harold Lehmann; Timothy R Sterling
Journal:  Am J Med       Date:  2007-05       Impact factor: 4.965

7.  Methods for Incorporating Patient Preferences for Treatments of Depression in Community Mental Health Settings.

Authors:  Paul Crits-Christoph; Robert Gallop; Caroline K Diehl; Seohyun Yin; Mary Beth Connolly Gibbons
Journal:  Adm Policy Ment Health       Date:  2017-09

8.  A six months follow-up on children less than 6 years old in contact with smear positive tuberculosis patients, varamin city, tehran, iran.

Authors:  Zohreh Aminzadeh; Rahim Taghizadeh Asl
Journal:  Int J Prev Med       Date:  2011-04

9.  The use of multi-criteria decision making models in evaluating anesthesia method options in circumcision surgery.

Authors:  Gulsah Hancerliogullari; Kadir Oymen Hancerliogullari; Emrah Koksalmis
Journal:  BMC Med Inform Decis Mak       Date:  2017-01-23       Impact factor: 2.796

10.  Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment.

Authors:  Jason C Hsu; Jia-Yu Lin; Peng-Chan Lin; Yang-Cheng Lee
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.